INCY 📈 Incyte - Overview

Incyte Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of therapeutics for various diseases, including hematology, oncology, inflammation, and autoimmunity. The company's product portfolio includes JAKAFI, a medication used to treat intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease. Additionally, Incyte offers MONJUVI and MINJUVI for the treatment of relapsed or refractory diffuse large B-cell lymphoma, as well as PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that targets oncogenic drivers in liquid and solid tumor types.

The company's other products include ICLUSIG, which is used to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia, and ZYNYZ, a medication for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. Incyte also offers OPZELURA cream for the treatment of atopic dermatitis. The company's clinical-stage products include retifanlimab, which is currently in Phase 3 clinical trials for the treatment of squamous cell carcinoma of the anal canal and non-small cell lung cancer. Other clinical-stage products include axatilimab, an anti-CSF-1R monoclonal antibody being developed for the treatment of chronic GVHD, as well as INCA033989, INCB160058, INCB99280, and INCB99318, which are being developed for various oncology and inflammatory indications.

Incyte has established collaboration agreements with several pharmaceutical companies, including Novartis and Lilly, to develop and commercialize its products. The company also has in-license agreements with Agenus, Merus, MacroGenics, and Syndax, and a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. Incyte sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers, and its common stock is listed on the NASDAQ stock exchange under the ticker symbol INCY. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003.

Incyte's research and development efforts are focused on creating innovative treatments for patients with serious diseases. The company's pipeline includes several promising products, such as INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. With its strong portfolio of products and collaborations, Incyte is well-positioned to continue making significant contributions to the field of biopharmaceuticals. The company's commitment to innovation and patient care has earned it a reputation as a leader in the biotechnology industry.